Can a simple virus test save transplant patients from cancer?

NCT ID NCT04189835

Completed Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated Jun 12, 2026 · Updated 30 times

Summary

This study followed 509 kidney transplant recipients to see if monitoring Epstein-Barr virus (EBV) levels in blood could help predict serious infections, a type of cancer called PTLD, or death. Participants had regular blood tests for EBV after their transplant. The goal was to find out if high or persistent virus levels signal that the immune system is too suppressed, putting patients at risk. The results may help doctors personalize immunosuppressive treatment to prevent complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aarhus University Hospital

Aarhus, Central Region Denmark, Denmark
Odense University Hospital

Odense, Region Syddanmark, Denmark
Rikshospitalet, Oslo Universitetssykehus

Oslo, Norway

Conditions

Explore the condition pages connected to this study.

EBV INFECTION EBV VIREMIA EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER